Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

NAGE Total Current Liabilities

All obligations due within one year.

Niagen Bioscience IncNASDAQ: NAGE

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities rises 9.5% from a year ago

Total current liabilities stood at $22.82M at the end of Q1 FY2026, up 9.5% from a year earlier and up 14.6% from the prior quarter. Over 3 fiscal years it compounded at +3.7% a year.

Context

  • Total current liabilities amounted to 20.0% of total assets at the end of Q1 FY2026, down 5.7 pp from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total current liabilities keeps rising in the next quarterly balance sheet after a +9.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$22.82M+14.6% QoQ
Last fiscal yearDec 2025
$19.92M+11.0% YoY
Year agoMar 2025
$20.84M+9.5% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.5%——
1 year+11.0%——
3-year CAGR+3.7%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
19.92M USD
Year-over-year change
+11.0%
4-year CAGR
+3.1%

Total Current Liabilities vs competitors

How NAGE compares with its peers on the latest reported figures

  • NAGE's Mar 2026 total current liabilities of $22.82M is the 8th highest of the 10 companies compared; the peer median is $47.17M.
  • Its year-over-year change of +9.5% is the 6th highest of 9, against a peer median of +32.4%.
  • Total current liabilities amounts to 20.0% of total assets for NAGE, versus a peer median of 16.9%.
NAGE Competitors Peer median
Total Current Liabilities for NAGE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AKBAAkebia Therapeutics, Inc.Mar 2026$173.88M +90.6%+7.9%48.0%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$89.49M +34.3%+15.0%17.7%
RGNXREGENXBIO Inc.Mar 2026$71.11M -33.4%-3.3%20.8%
KALVKalVista Pharmaceuticals, Inc.Dec 2025$57.36M ——17.1%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$47.17M +81.0%+46.3%8.9%
ZVRAZevra Therapeutics, Inc.Mar 2026$47.03M +74.3%+48.4%16.9%
PRTAProthena Corporation plcMar 2026$32.52M -32.9%-6.6%9.3%
NAGENiagen Bioscience IncMar 2026$22.82M +9.5%+3.7%20.0%
KROSKeros Therapeutics, Inc.Mar 2026$12.85M -67.4%+7.3%4.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$12.11M +30.5%-4.4%4.8%
Peer median (excluding NAGE) $47.17M+32.4%+7.6%16.9%

Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents28.02M20.29M27.17M44.51M64.79M
Short-term Investments00000
Net Receivables5.23M8.48M5.23M7.77M9.74M
Inventory13.6M14.68M14.53M9.19M20.42M
Other Current Assets200K3.12M2.6M2.63M1.85M
Total Current Assets48.91M46.57M49.53M64.1M96.81M
Property, Plant & Equipment (Net)7.36M6.32M4.54M3.45M3.52M
Goodwill00000
Intangible Assets857K671K510K359K5.66M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets723K497K383K368K425K
Total Non-current Assets8.94M7.49M5.43M4.18M9.6M
Total Assets57.84M54.06M54.96M68.28M106.41M
Account Payables10.42M9.68M10.23M8.53M10.8M
Short-term Debt00001M
Tax Payables00000
Deferred Revenue161K157K195K611K0
Other Current Liabilities00008.12M
Total Current Liabilities17.61M17.87M20.62M17.95M19.92M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)4.35M3.96M3.31M2.58M2.67M
Other Non-current Liabilities00005.47M
Total Non-current Liabilities8.5M7.52M5.89M4.24M9.95M
Total Liabilities26.11M25.39M26.51M22.18M29.87M
Common Stock68K74K75K77K79K
Retained Earnings(168.95M)(185.49M)(190.46M)(181.91M)(164.53M)
Accumulated OCI(2K)(3K)(4K)(4K)(9K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity31.73M28.67M28.46M46.09M76.53M
Total Debt4.7M4.26M3.28M2.65M2.82M
Net Debt(23.32M)(16.03M)(23.9M)(41.86M)(61.97M)

Niagen Bioscience Inc

NASDAQ:NAGE

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.